Tuesday , March 18 2025
Home / Media OutReach (page 1340)

Media OutReach

World Green Building Leaders Join Forces to Support Hong Kong’s First “Advancing Net Zero” Ideas Competition for Carbon Neutrality

Chair of the WorldGBC, Mr William McDonough, Ms Meaghan Lloyd of Gehry Partners and Professor Jiang Yi from Tsinghua University will be on the Jury Panel to offer professional insights to the contestants HONG KONG SAR – Media OutReach – 26 March 2021 – The Hong Kong Green Building Council (HKGBC), a non-profit …

Read More »

World Green Building Leaders Join Forces to Support Hong Kong’s First “Advancing Net Zero” Ideas Competition for Carbon Neutrality

Chair of the WorldGBC, Mr William McDonough, Ms Meaghan Lloyd of Gehry Partners and Professor Jiang Yi from Tsinghua University will be on the Jury Panel to offer professional insights to the contestants HONG KONG SAR – Media OutReach – 26 March 2021 – The Hong Kong Green Building Council (HKGBC), a non-profit …

Read More »

M1 Reveals Made-to-Measure Bespoke Mobile Plans and Debuts ‘Be’ Campaign’s Inspirational Stories

M1’s made-to-measure Bespoke mobile plans are the next step in the journey to revolutionise Singapore’s telecommunications industry. Reflected in the newly unveiled human-centred stories behind the ‘Be’ campaign, these incredibly flexible mobile plans give customers the freedom to be themselves. SINGAPORE – Media OutReach – 26 March 2021 – Following …

Read More »

M1 Reveals Made-to-Measure Bespoke Mobile Plans and Debuts ‘Be’ Campaign’s Inspirational Stories

M1’s made-to-measure Bespoke mobile plans are the next step in the journey to revolutionise Singapore’s telecommunications industry. Reflected in the newly unveiled human-centred stories behind the ‘Be’ campaign, these incredibly flexible mobile plans give customers the freedom to be themselves. SINGAPORE – Media OutReach – 26 March 2021 – Following …

Read More »

Genor Biopharma Releases Its Annual Results for 2020

Significant progresses in IND, clinical development, NDA/BLA, commercialization, BD and financing NDA/BLA progress – GB226 (Geptanolimab) Priority Review for PTCL, GB242 (infliximab (Remicade) biosimilar) under Review Clinical development – Three products’ registrational pivotal trails completed (GB226,GB221,GB242), GB491 (CDK 4/6) for 1L and 2L HR+/HER2- breast cancer bridging studies EC approved, …

Read More »

Genor Biopharma Releases Its Annual Results for 2020

Significant progresses in IND, clinical development, NDA/BLA, commercialization, BD and financing NDA/BLA progress – GB226 (Geptanolimab) Priority Review for PTCL, GB242 (infliximab (Remicade) biosimilar) under Review Clinical development – Three products’ registrational pivotal trails completed (GB226,GB221,GB242), GB491 (CDK 4/6) for 1L and 2L HR+/HER2- breast cancer bridging studies EC approved, …

Read More »